ArticleFrontiers in molecular biosciences2025
Analysis of blood untargeted metabolomic characteristics of different subtypes of rosacea.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rosacea is a chronic inflammatory skin disease characterized by vascular and neurological dysregulation, presenting with diverse clinical subtypes whose pathological mechanisms remain incompletely elucidated. Recent studies suggest that metabolic dysregulation may play a key role in disease onset and progression; however, systematic metabolomic studies targeting different subtypes remain limited. Objective: This study employed untargeted metabolomic analysis to systematically compare plasma metabolic characteristic differences between patients with erythematotelangiectatic rosacea (ETR), papulopustular rosacea (PPR), and healthy controls (HC), aiming to identify potential disease biomarkers and provide new insights for understanding the pathogenesis of rosacea. Methods: Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) was used to compare metabolic profiles of plasma samples from ETR, PPR, and HC groups. Key differential metabolites identified were subjected to correlation analysis with disease severity and skin physiological parameters. Results: ETR patients primarily involved amino acid metabolism, carbon metabolism, and cholesterol metabolism pathways, with key metabolites including upregulated SSA and 2,3-DHPA, and downregulated TCDCA and Met. PPR patients primarily involved tryptophan and linoleic acid metabolism pathways, with key metabolites including upregulated 12-HSA, DGLA, and 5-ALA, and downregulated 5-HTP and 3-HPPA. Metabolic differences between different rosacea subtypes were associated with steroid hormone biosynthesis. DGLA showed positive correlation with disease severity, while 5-HTP showed negative correlation with disease severity. Met was closely related to skin barrier function. Both 12-HSA and DGLA showed positive correlation with sebum secretion. Conclusion: These findings elucidate the metabolic characteristics of rosacea and their associations with disease severity and skin physiological parameters, providing new theoretical foundation and potential targets for subtype diagnosis and precision treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.